Clinical and Translational Gastroenterology最新文献

{"title":"Relationship of Intestinal Ultrasound With Clinical, Biochemical, and Endoscopic Disease Severity in Acute Severe Ulcerative Colitis: A Blinded, Prospective Study.","authors":"Phillip Gu, David Ziring, Puja V Khanna, Waseem Ahmed, Eric Vasiliauskas, Andres Yarur, Stephan Targan, Dermot P B McGovern, Shervin Rabizadeh, Phillip Fleshner, Maria T Abreu, Gil Y Melmed","doi":"10.14309/ctg.0000000000000881","DOIUrl":"10.14309/ctg.0000000000000881","url":null,"abstract":"<p><strong>Introduction: </strong>The utility of intestinal ultrasound (IUS) for acute severe ulcerative colitis (ASUC) is understudied. We correlated IUS to clinical, biochemical, and endoscopic disease severity in ASUC.</p><p><strong>Methods: </strong>In a blinded, prospective study of 20 ASUC subjects, we analyzed standard IUS parameters (bowel wall thickening, vascular flow, wall stratification) and UC IUS indices (International Bowel Ultrasound Segmental Activity Score (IBUS-SAS), Milan-UC, UC-IUS) alongside modified Mayo symptoms scores, C-reactive protein (CRP), albumin, and UC Endoscopic Index of Severity (UCEIS). Spearman correlations were performed (rs). Area under the curve (AUC) determined utility of IUS for detecting severe endoscopic disease.</p><p><strong>Results: </strong>All IUS indices correlated with stool frequency (rs: 0.45-0.58, P < 0.001), CRP (rs: 0.56-0.59, P < 0.02), and UCEIS (rs: 0.54-0.69, P < 0.03). IBUS-SAS (AUC 0.91) and Milan-UC (AUC 0.93) outperformed IUS-UC (AUC 0.82) for detecting UCEIS ≥5. Loss of bowel wall stratification correlated strongest with CRP (rs: 0.8, P = 3.61e -8 ) and UCEIS (rs: 0.50, P = 0.047).</p><p><strong>Discussion: </strong>IUS offers an accurate and noninvasive method to evaluate ASUC severity and treatment response.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00881"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144494885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing Trends on Intercostal Chest Tube Placement for Hepatic Hydrothorax Despite Negative Impact on Patient Outcomes: A National Inpatient Sample Database Analysis.","authors":"Aishwarya Thakurdesai, Sheel Patel, Winston Dunn, Paul Kwo, Ashwani K Singal","doi":"10.14309/ctg.0000000000000889","DOIUrl":"10.14309/ctg.0000000000000889","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatic hydrothorax (HH) significantly contributes to morbidity in decompensated cirrhosis. Intercostal chest tube (ICT) insertion is discouraged in HH management. We examined trends in ICT use and impact on outcomes in hospitalized HH patients.</p><p><strong>Methods: </strong>A retrospective cohort study (October 2015-December 2019) was conducted using the National Inpatient Sample to identify HH hospitalizations among patients with decompensated cirrhosis. Propensity score matching compared patients who received ICT with those who did not. Outcomes included in-hospital mortality (IHM), length of stay (LOS), total charges (TC), and complications.</p><p><strong>Results: </strong>Among 127,627 cirrhosis hospitalizations, 7,843 (6.2%) had HH. Compared with those without HH, these patients had longer LOS, higher TC, and more acute kidney injury and sepsis ( P < 0.001). HH was not associated with increased IHM, but ICT and spontaneous bacterial empyema were, each conferring ∼1.5-fold higher odds. ICT was used in 1,312 HH cases (16.7%), with increasing use over time ( P = 0.037). In a matched cohort of HH hospitalizations (1,277 with ICT; 2,554 without), ICT use was linked to higher IHM (11.6% vs 8.5%), longer LOS (14.6 vs 8.7 days), and greater TC ($196,000 vs $112,000). Complications were more frequent with ICT: acute kidney injury (45% vs 39%), sepsis (18% vs 10%), and spontaneous bacterial empyema (12.5% vs 2%) ( P < 0.001). ICT use was associated with 44% higher odds of IHM, OR (95% confidence intervals): 1.44 (1.15-1.81).</p><p><strong>Discussion: </strong>HH occurs in 6.2% of cirrhosis hospitalizations, with 1 of 6 receiving ICT. ICT use is increasing despite poorer outcomes and greater resource utilization. Studies targeted toward better patient selection and provider education are needed to mitigate ICT use in HH.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00889"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Immune-Related Adverse Events on Survival in Patients With Gastrointestinal Cancer Treated With Immune Checkpoint Inhibitors: A Meta-Analysis.","authors":"Wenxing Yan, Lijuan Qin, Yingying Han, Xueli Jia, Juan Wu","doi":"10.14309/ctg.0000000000000875","DOIUrl":"10.14309/ctg.0000000000000875","url":null,"abstract":"<p><strong>Introduction: </strong>Immune-related adverse events (irAEs) stemming from off-target immune activation have been associated with improved survival outcomes in various cancers. Nonetheless, the influence of irAEs on survival among gastrointestinal (GI) cancer patients treated with immune checkpoint inhibitors (ICIs) remains ambiguous. The aim of this meta-analysis was to clarify the relationship between irAEs and survival outcomes in this patient cohort.</p><p><strong>Methods: </strong>We systematically searched PubMed, Embase, and Web of Science to identify relevant observational studies with longitudinal data. Studies reported on overall survival (OS) or progression-free survival (PFS) among patients with GI cancer treated with ICIs, comparing those with irAEs with those without. We calculated pooled hazard ratios (HRs) and 95% confidence intervals (CIs) using a random-effects model to account for heterogeneity.</p><p><strong>Results: </strong>Our analysis included 22 retrospective cohort studies comprising 2,935 patients; 1,142 (38.9%) experienced irAEs. The pooled analyses indicated a significant association between the occurrence of irAEs and improved OS (HR: 0.45, 95% CI 0.36-0.57, P < 0.001, I2 = 56%) and PFS (HR: 0.44, 95% CI 0.34-0.57, P < 0.001, I2 = 65%). Subgroup analyses supported the consistency of these findings across tumor location, study quality scores, follow-up duration, and analytical models, with no significant differences noted ( P for subgroup differences all >0.05).</p><p><strong>Discussion: </strong>The presence of irAEs in patients with GI cancer receiving ICIs correlates with significantly better OS and PFS. This suggests that irAEs may be a potential biomarker for predicting treatment response.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e00875"},"PeriodicalIF":3.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Electroporation for the Treatment of Pancreatic Ductal Adenocarcinoma: A Systematic Review of Preclinical and Clinical Studies.","authors":"Gabriel Marcellier, Theo Le Berre, Paul Rivallin, Marie Frenea-Robin, Frédéric Prat","doi":"10.14309/ctg.0000000000000911","DOIUrl":"10.14309/ctg.0000000000000911","url":null,"abstract":"<p><strong>Introduction: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with poor prognosis and limited treatment options. Electroporation-based therapies, such as electrochemotherapy (ECT) and irreversible electroporation (IRE), could be promising alternatives. ECT combines reversible electroporation with chemotherapy, enhancing intracellular drug uptake, while IRE leads to nonthermal tumor ablation. Both have been suggested as immunotherapy potentiators (electroimmunotherapy) in some tumor locations. We conducted a systematic review to evaluate the efficiency and safety of ECT, IRE, and immunoelectroporation in PDAC treatment.</p><p><strong>Methods: </strong>We searched Medline, Embase, Cochrane, and Google-Scholar for ECT, IRE, and electroimmunotherapy following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. For ECT and electroimmunotherapy, regarding the scarcity of the data, we described independently each study protocol and results. For IRE, we collected protocol, efficiency, and safety data to provide a global analysis.</p><p><strong>Results: </strong>Fifteen studies described the effects of ECT for PDAC treatment: Safety and efficiency were promising in both preclinical and human models. Thirty-eight clinical studies including 2,245 patients were analyzed for IRE, with patients mostly treated for locally advanced pancreatic cancer and a median overall survival of 17.2 months at the expanse of a 36% adverse event rate, half of which severe. Seven (preclinical and clinical) studies investigated electroimmunotherapy suggesting significant potentiation of immunotherapy in both preclinical and human models.</p><p><strong>Discussion: </strong>In the largest systematic review to date regarding electroporation in PDAC treatment, analysis of study results plead against the use of IRE but highlight the potential benefits of ECT and electroimmunotherapy.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using GLP-1 Receptor Agonists.","authors":"Samita Garg, Din Hoxha, David Long, Sara Valencia, Qijun Yang, Anthony Lembo, John J Vargo, Dian-Jung Chiang","doi":"10.14309/ctg.0000000000000913","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000913","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. While they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aims to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenoma and sessile serrated adenoma (SSP) polyp detection.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at XXX. Adults who used a GLP-1RA within one week of colonoscopy formed the treatment group; patients not on GLP-1RA (non-users) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, gender, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use.</p><p><strong>Results: </strong>Among 49,987patients (4,269 GLP-1RA users, 45,718non-users), GLP-1RA use was associated with increased odds of inadequate bowel preparation (OR 1.23, 95% CI 1.04-1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59-2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57-0.89).</p><p><strong>Conclusion: </strong>GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection appear unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dupilumab for adult and adolescent patients with primary eosinophilic colitis.","authors":"Twan Sia, Leeon Bacchus, Aparna Kumar, Lina Fikri, Rachel Solecki, Ramin Herath, Yeelin Bacchus, Audrey Apollon, Margaret Werd, Aseelah Ashraf, Elaine Wu, Dan Bahar, John Leung","doi":"10.14309/ctg.0000000000000908","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000908","url":null,"abstract":"<p><strong>Introduction: </strong>Eosinophilic colitis (EoC) currently has limited options to induce histologic and clinical remission. Dupilumab is a human monoclonal antibody against the interleukin-4 receptor ɑ subunit effective in eosinophilic esophagitis (EoE) and other non-EoE eosinophilic gastrointestinal disorders (non-EoE EGIDs).</p><p><strong>Methods: </strong>We conducted a retrospective chart review to assess the histoclinical response of patients with EoC treated with dupilumab.</p><p><strong>Results: </strong>Of 4 included patients, all 4 improved histologically, with 3 patients attaining histologic remission. All patients' symptom scores significantly improved, and 1 patient was asymptomatic on dupilumab.</p><p><strong>Discussion: </strong>This retrospective case series provides preliminary evidence that dupilumab may be an effective treatment option for EoC.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EVALUATING THE PROGNOSTIC VALUE OF THE MELD 3.0 SCORE IN PREDICTING MORTALITY IN CIRRHOSIS PATIENTS WITH ACUTE VARICEAL BLEEDING.","authors":"Tram Que Nguyen Pham, Thong Duy Vo","doi":"10.14309/ctg.0000000000000909","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000909","url":null,"abstract":"<p><strong>Introduction: </strong>Acute variceal bleeding (AVB) is a severe complication of cirrhosis, with a 6-week mortality rate of up to 15-20%. Early risk prediction is essential for guiding management. MELD 3.0, a refined version of the original MELD score, incorporates additional variables (gender, sodium, albumin, capped creatinine) to improve short-term mortality prediction. This study assessed MELD 3.0's utility in predicting 6-week mortality in cirrhotic patients with AVB, in comparison with MELD, Glasgow-Blatchford Score (GBS), and AIMS65.</p><p><strong>Methods: </strong>A prospective cohort of cirrhotic patients with AVB admitted to Cho Ray Hospital (Nov 2023-May 2024) was studied. The primary outcome was 6-week mortality; in-hospital mortality was secondary. The predictive performance of MELD 3.0, MELD, GBS, and AIMS65 was evaluated using AUCROC.</p><p><strong>Results: </strong>Among 212 patients, in-hospital and 6-week mortality rates were 4.7% and 19.8%, respectively. For in-hospital mortality, MELD 3.0 showed the highest AUC (0.88), followed by MELD (0.80), AIMS65 (0.74), and GBS (0.59). For 6-week mortality, MELD 3.0 again outperformed others (AUC: 0.81), vs. MELD (0.75), AIMS65 (0.66), and GBS (0.61) (all p < 0.05). A MELD 3.0 cut-off ≥ 20 predicted >25% 6-week mortality (sensitivity 69.1%, specificity 83.5%).</p><p><strong>Conclusion: </strong>MELD 3.0 is a strong predictor of early mortality in cirrhotic patients with AVB. A cut-off ≥ 20 may help identify high-risk patients requiring prompt intensive care.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The associations between pancreatic fat infiltration and its combination with the triglyceride glucose index and the risk of coronary calcification: A multicenter study.","authors":"Hao Zhou, Xin Chen, Yiping Zhang, Yajie Wang, Dingzhe Zhang, Cheng Wang, Bin Qin, Xifa Gao, Yongkang Liu, Dongling Lv, Jianhua Wang, Xiao Chen","doi":"10.14309/ctg.0000000000000905","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000905","url":null,"abstract":"<p><strong>Introduction: </strong>Intrapancreatic fat deposition is related to insulin resistance and type 2 diabetes mellitus. However, the association between intrapancreatic fat deposition and coronary artery disease has not been well studied. In this study, we investigated the associations between intrapancreatic fat deposition alone or in combination with triglyceride glucose index (TYG) and the risk of coronary artery calcification (CAC) in a general population.</p><p><strong>Methods: </strong>A total of 9479 participants who underwent computed tomography (CT) scans for lung cancer screening from 2018-2020 were included in this study. The TYG index was calculated via the following equation: Ln[fasting glucose (mg/dL)×fasting TG (mg/dL)/2]. Pancreatic CT attenuation was used as a marker of intrapancreatic fat deposition. CAC was evaluated on noncardiogram-gated chest CT.</p><p><strong>Results: </strong>CAC was detected in 2447 of 9479 participants. The prevalence of CAC was significantly lower in subjects with high pancreatic CT attenuation (37.8% in the first quartile (Q1) vs 17.8% in the fourth quartile (Q4), p < 0.001). Pancreatic CT attenuation was associated with the occurrence of CAC (odds ratio (OR) = 0.82, 95% confidence interval (CI): 0.69-0.97, Q4 vs Q1). The area under the curve of the combination of pancreatic CT attenuation and the TYG index was significantly greater than that of TYG and pancreatic CT attenuation alone in identifying CACs (0.646 vs 0.596 and 0.612, p < 0.001).</p><p><strong>Conclusions: </strong>Intrapancreatic fat deposition was associated with CAC, and the combination of pancreatic CT attenuation and the TYG index performed better than TYG or pancreatic CT attenuation alone in identifying CACs.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential Item Functioning of the Patient Health Questionnaire-9 in Decompensated Cirrhosis.","authors":"Nneka N Ufere, Chengbo Zeng, Daniel Shalev, Andrea L Pusic, Kurt Kroenke, Maria Edelen","doi":"10.14309/ctg.0000000000000906","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000906","url":null,"abstract":"<p><strong>Introduction: </strong>We examined whether the symptom expression of depression as assessed using the Patient Health Questionnaire-9 (PHQ-9) depression screening tool differs between patients with decompensated cirrhosis (DC) compared to primary care patients.</p><p><strong>Methods: </strong>Study included 218 DC patients (91% Child-Pugh Class B/C) recruited from a liver transplant center and a real-world cohort of 436 outpatients from four primary care clinics in a large tertiary academic health system who completed the PHQ-9. We calculated positive screening rates for depression (PHQ-9 cutoff score of 10) for both cohorts. We evaluated PHQ-9 items for differential item functioning (DIF) in both cohorts within an Item Response Theory (IRT) framework. We compared DIF-adjusted and unadjusted IRT scores to characterize the impact of DIF on PHQ-9 total scores.</p><p><strong>Results: </strong>Positive screening rates using a PHQ-9 cutoff score of 10 were 39% and 30% for DC and primary care patients respectively. Three PHQ-9 somatic symptom items (sleep problems, low energy, psychomotor agitation or retardation) showed significant DIF, with DC more likely than primary care patients with similar levels of depression severity to endorse these symptoms. DIF-adjusted scores suggested a one-point increase (PHQ-9 cutoff score of 11) in the screening threshold for DC patients.</p><p><strong>Conclusions: </strong>Equating for depression severity, we found differences in the symptom expression of depression for DC patients relative to primary care patients. Our findings highlight the need for future clinical and basic research into the diagnostic performance of depression screening tests and the phenomenology of depression in patients with DC.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Machine Learning and Multiomics Analyses to Identify Immune-Related Biomarkers and Mechanisms in Primary Biliary Cholangitis.","authors":"Zhiyu Zeng, Jian Fang, Li Chen, Ying Liang, Dongliang Li, Lei Xia, Longke Xie","doi":"10.14309/ctg.0000000000000907","DOIUrl":"10.14309/ctg.0000000000000907","url":null,"abstract":"<p><strong>Introduction: </strong>Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that gradually progresses, making early diagnosis and treatment challenging. Reliable biomarkers could enhance diagnostic accuracy and therapeutic development.</p><p><strong>Methods: </strong>This study analyzed 3 publicly available gene expression data sets from the Gene Expression Omnibus database: GSE119600 (90 patients with PBC and 47 healthy controls), GSE159676 (12 PBC patients and 6 controls), and GSE61260 (11 patients with PBC and 38 controls). To identify genes closely linked to PBC, we applied machine learning techniques, including Least Absolute Shrinkage and Selection Operator, Support Vector Machine-Recursive Feature Elimination, and random forest. We subsequently conducted gene set enrichment and immune cell infiltration analyses to investigate their biological significance. IN addition, potential drug interactions were explored through the Drug Gene Interaction Database, and a competing endogenous RNA regulatory network was developed to examine gene regulation. Finally, the expression of selected genes was validated through multiplex immunofluorescence staining of liver tissue samples from patients with PBC.</p><p><strong>Results: </strong>We identified proteasome subunit beta 7, TRAF family member associated nuclear factor kappa-light-chain-enhancer of activated B cells activator Albumin (TANK)-binding kinase 1, solute carrier family 29 member 1, and natural killer cell receptor 2B4 as key genes associated with PBC; these genes were significantly enriched in immune-related pathways and strongly correlated with immune regulation. Drug target prediction indicated that some genes could interact with existing immunomodulators or anticancer drugs. Competing endogenous RNA network analysis revealed that TANK-binding kinase 1, solute carrier family 29 member 1, and natural killer cell receptor 2B4 interact with multiple miRNAs and long noncoding RNAs, potentially regulating the immune microenvironment of PBC through noncoding RNA mechanisms. Immunofluorescence staining confirmed that these genes were highly expressed in liver tissues from patients with PBC.</p><p><strong>Discussion: </strong>By integrating machine learning and functional analyses, this study identified 4 genes that may serve as potential biomarkers for PBC. Their involvement in immune regulation suggests possible applications in both diagnosis and therapy. Further studies are necessary to explore their clinical relevance and therapeutic potential.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}